← Back to headlines
Bristol Myers Wins FDA Priority Review for Multiple Myeloma Therapy
Bristol Myers has received FDA priority review for its multiple myeloma therapy, indicating a potential acceleration in the drug's approval process.
17 Feb, 19:12 — 17 Feb, 19:12
ℹOnly 1 source covers this story
